Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00920855 · OUTCOME

Kaplan-Meier Estimate for Progression-Free Survival

Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma · Source last updated 2012-10-04

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
MEDIAN
Unit
months
Interval / dispersion
95% Confidence Interval
Time frame
up to 23 months

What was measured

Progression free survival is the time between the date of initiation of therapy to progressive disease (PD) or death from any cause, whichever occurs first. See outcome #4 for a definition of PD.

Analysis population: Safety population

Groups in this outcome

Bendamustine and Bortezomib - Overall

Bendamustine in escalating doses of 50, 70 or 90 mg/m\^2 as combination therapy with bortezomib at 1.0 mg/m\^2/dose administered for up to eight 28 day cycles. Participants whose disease has not progressed at the end of the eight cycles will be followed until disease progression or death.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Bendamustine and Bortezomib - Overall40

Reported measurements

Source class 1
Values in months · Interval/dispersion: 95% Confidence Interval
GroupValueSpreadLowerUpperComment
Bendamustine and Bortezomib - Overall15.21Not reported5.2216.63Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        5.22
        upper Limit
        16.63
        value
        15.21
denoms
  1. counts
    1. group Id
      OG000
      value
      40
    units
    Participants
description
Progression free survival is the time between the date of initiation of therapy to progressive disease (PD) or death from any cause, whichever occurs first. See outcome #4 for a definition of PD.
dispersion Type
95% Confidence Interval
groups
  1. description
    Bendamustine in escalating doses of 50, 70 or 90 mg/m\^2 as combination therapy with bortezomib at 1.0 mg/m\^2/dose administered for up to eight 28 day cycles. Participants whose disease has not progressed at the end of the eight cycles will be followed until disease progression or death.
    id
    OG000
    title
    Bendamustine and Bortezomib - Overall
param Type
MEDIAN
population Description
Safety population
reporting Status
POSTED
time Frame
up to 23 months
title
Kaplan-Meier Estimate for Progression-Free Survival
type
SECONDARY
unit Of Measure
months

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice